[A18-01] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V
Last updated 16.04.2018
Project no.:
A18-01
Commission:
Commission awarded on 05.01.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Children's and adolescents' health
Children aged 6 to 12 years who are infected with HIV-1
No study data; added benefit not proven in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-61 | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-116 | Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-07-05 A G-BA decision was published.